

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-44 (Canceled).

45. (New): An oral dosage form comprising:

(i) a first composition, which is an immediate release composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate or a hydrate thereof;

(ii) a second composition, which is a modified release composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate or a hydrate thereof; and

(iii) a third composition comprising a coating enteric layer, wherein the third composition comprises two openings extending completely through the third composition, wherein one opening provides access to the first composition and the other opening provides access to the second composition.

46. (New) An oral dosage form according to claim 45, wherein the coating enteric layer erodes in the pH range from 4.5 to 8.

47. (New): An oral dosage form according to claim 45, which dosage form is arranged to release the 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate or a hydrate thereof such that the mean maximum plasma level concentration value of the drug is maintained independent of food during use.

48. (New): An oral dosage form according to claim 45, which dosage form is arranged to release the 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate or a hydrate thereof such that the mean area under the plasma concentration versus time curve over the dosing interval at steady state is maintained independent of food during use.

49. (New): An oral dosage form according to claim 45, which dosage form is arranged to release the 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate or a hydrate thereof so that both the mean maximum plasma level concentration and the mean area under the plasma concentration versus time curve over the dosing interval at steady state are maintained independent of food during use.

50. (New): A method for the treatment of diabetes mellitus, metabolic syndrome, impaired glucose tolerance or impaired fasting glucose in a human or non-human mammal, which method comprises administering the oral dosage form according to claim 45 to said human or non-human mammal.